版本:
中国

BRIEF-VBI Vaccines reports positive outcome from phase III pre-ind discussions with the FDA for hepatitis B vaccine, Sci-B-Vac

June 19 Vbi Vaccines Inc

* Vbi Vaccines reports positive outcome from phase III pre-ind discussions with the FDA for Hepatitis B vaccine, Sci-B-Vac(tm)

* VBI Vaccines - confirm initial ind for Sci-B-Va will not require any additional clinical studies to support pivotal, global phase III clinical program​

* Says ‍VBI plans to submit ind in second half of 2017, together with clinical trial applications for Europe and Canada​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐